Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

• Published in: OncoTargets and therapy Vol. 10; pp. 4239 - 4250
• Main Authors: Creelan, Ben, Gabrilovich, Dmitry, Gray, Jhanelle, Williams, Charles, Tanvetyanon, Tawee, Haura, Eric, Weber, Jeffrey, Gibney, Geoffrey, Markowitz, Joseph, Proksch, Joel, Reisman, Scott, McKee, Mark, Chin, Melanie, Meyer, Colin, Antonia, Scott
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2017; Dove Medical Press
• Subjects: Antifungal agents; Cancer; Cell growth; Clinical Trial Report; Drug dosages; Electrocardiography; Family medical history; Human subjects; Immunotherapy; Kinases; Lung cancer; Melanoma; Oncology; Pharmacodynamics; Pharmacokinetics; Tumors; United States > US; North Chicago Illinois; non-small cell lung cancer; melanoma; antioxidant inflammation modulator; immuno-oncology; nitrotyrosine; bardoxolone methyl; nitric oxide synthase; myeloid-derived suppressor cells
• DOI: 10.2147/OTT.S136992
• ISSN: 1178-6930

Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize pharmacokinetic and pharmacodynamic parameters, and assess antitumor activity. Omaveloxolone was administered orally once daily continuously in a 28-day cycle for patients with stage 4 relapsed/refractory melanoma or non-small cell lung cancer. An accelerated titration design was employed until a grade 2-related adverse event (AE) occurred. A standard 3+3 dose escalation was employed. Single-dose and steady-state plasma pharmacokinetics of the drug were characterized. Downstream Nrf2 activation was assessed in peripheral blood mononuclear cells by quantification of target gene mRNA expression. Omaveloxolone was tested at four dose levels up to 15 mg given orally once daily. No dose-limiting toxicities were detected, and the maximum tolerated dose was not determined. All drug-related AEs were either grade 1 or 2 in severity, and none required clinical action. The most common drug-related AEs were elevated alkaline phosphatase (18%) and anemia (18%). No drug interruptions or reductions were required. Omaveloxolone was rapidly absorbed and exhibited proportional increases in exposure across dose levels. With some exceptions, an overall trend toward time-dependent and dose-dependent activation of Nrf2 antioxidant genes was observed. No confirmed radiologic responses were seen, although one lung cancer subject did have stable disease exceeding 1 year. Omaveloxolone has favorable tolerability at biologically active doses, although this trial had a small sample size which limits definitive conclusions. These findings support further investigation of omaveloxolone in cancer.